The price of the cancer drug, Kymriah, is “dramatically higher” than other specialty drugs like it on the market and the healthcare system isn’t set up to pay for it, Dr. Miller wrote.
Kymriah, a CAR-T cell leukemia therapy, uses patients’ genetically modified immune cells to fight the disease. The drug is administered to patients just once, resulting in a high price tag as Novartis has a single opportunity per patient to redeem its investment, according to Bloomberg.
“The healthcare system isn’t set up for this type of economic model,” wrote Dr. Miller. “We need a new payment model.”
Paying for these types of therapies will require collaboration among payers, pharmaceutical companies and policy makers, he added.
More articles on supply chain:
California seeks disciplinary action against UC Los Angeles pharmacy after investigation reveals it distributed drugs with expired ingredients
6 drugmakers in the headlines
Rural hospitals struggle to stock rare disease drugs blocked from 340B discounts
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
